log
     Login   |   Register   
img
 
EDITORIAL BOARD
 
  Dr. DEEPANWITA SENGUPTA  
 
Address 1 :
Address 2 :
Title : Dr.
First Name : DEEPANWITA
Last Name : SENGUPTA
University/Institution : Stanford university
Phone # : 5012319247
Email ID : deepasen@stanford.edu
City : San mateo
Country : United States
State : California
Zipcode : 94403
Department : Biology
Company Name :
Area of Research
Biochemistry, molecular biology, epigenetics, cancer, tumor
Area of Expertise
Biochemistry, molecular biology, epigenetics, cancer, tumor
Brief Description of Research Interest :
My primary focus for both my PhD and postdoctoral studies have been chromatin biology and it’s impact on oncology. Briefly, in my PhD, I focused on the role of histone methyl transferase EZH2 in melanoma, where my work involved understanding complex EZH2-mediated epigenetic mechanisms in melanoma resulting in repression of tumor suppressor genes such as E-cadherin and RUNX3. Alongside, I also pursued another study unveiling the complex epigenetic-mediated regulation of c-Myc in Merkel Cell Carcinoma.

My post-doctoral work involves identifying the role of the epigenetic regulator NSD2 in oncogenesis independently and in conjunction with other oncogenic drivers such as Ras. Alongside, I am also investigating the contribution of NSD2 gain of function mutation in B cell development leading to lymphoid disorders.
Representative Publications :
 P Zanoni*, K Steindl*, D Sengupta*, et. al. (2021). “Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype.” Genetics in Medicine, 1-10 (* Authors contributed equally), 
2. G Yuan, N Flores, S Hausmann, S Lofgren, V Kharchenko, M Ibanez, D Sengupta, X Lu, I Czaban, D Azhibek, S Vicent, W Fischle, M Jaremko, B Fang, I Wistuba, K Chua, J Roth, J Minna, N Shao, L Jaremko,  P Mazur & O Gozani (2021). “Elevated NSD3 histone methylation activity drives squamous cell lung cancer” Nature, 590 (7846), 504–508
3. W Li, W Tian, G Yuan, P Deng, D Sengupta, Z,Cheng, Y Cao, J Ren, Y Qin, Y Zhou, Y Jia, O Gozani, DJ  Patel, Z Wang (2021). Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.  Nature, 590 (7846), 498-503.
4. B Shields, F Mahmoud, E Taylor, SD Byrum, D Sengupta, B Koss, G Baldini, S Ransom, K Cline, S  Mackintosh, R Edmondson, S Shalin, and AJ Tackett (2017). “Indicators of responsiveness to immune  checkpoint inhibitors.” Sci Rep, 7(1). 1-12.
5. D Sengupta, AJ Tackett (2016). “Proteomic Findings in Melanoma.” J Proteomics & Bioinform 9 (4).
6. D Sengupta, N Avaritt, S Shalin, A Tackett (2016). “Enhancer of zeste homolog 2 (EZH2) inhibition in  metastatic melanoma promotes tumor regression in vivo.” Cancer Research 76 (14 Supplement), 1146- 1146.
7. D Sengupta, S Byrum, N Avaritt, L Davis, L Orr, S Mackintosh, S Shalin, A Tackett (2016). “Quantitative  histone mass spectrometry identifies elevated histone H3 lysine 27 trimethylation in melanoma.” Molecular  and Cellular Proteomics, 15(3), 765-775.
8. D Sengupta, A Kannan, M Kern, M Moreno, E Vural, B Stack, J Suen, A Tackett and L Gao (2015).  “Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression  in Merkel cell carcinoma.” Epigenetics, 10(6), 460-466.
9. D Sengupta, N Avaritt, A Tackett (2015). “EZH2 Overexpression in Malignant Melanoma Represses E- cadherin and Promotes Invasion.” The FASEB Journal 29 (1 Supplement), 877.8.
10. U Udensi, A Tackett, S Byrum, N Avaritt , D Sengupta, et al. (2014). “Proteomics-Based Identification of  Differentially Abundant Proteins from Human Keratinocytes Exposed to Arsenic Trioxide.” J  Proteomics Bioinform 7 (7): 166-178.
11. N Avaritt, F Mahmoud, D Sengupta, I Makhoul, L Hutchins, A Tackett (2014). “Role of the EZH2 histone  ethyltransferase in melanoma.” Pigment Cell & Melanoma Research 27 (6).
12. N Avaritt, M Fade, M Reynolds, D Sengupta, I Makhoul, S Shalin, A Tackett (2013). “Cutaneous  Melanoma: Molecular Mechanisms and Current Therapeutic Approaches.” Melanoma: Molecular  Biology, Risk Factors and Treatment Options Chapter 6 pp.137-154. Hauppauge, New York: Nova  Science Publishers.
PEER-REVIEWED PUBLICATIONS
Resume : Download
 
     
 
 
footer